Home » Research » SARC Clinical Trials
Every day, our community of researchers, investigators, scientists, sarcoma centers, and biotech and pharmaceutical companies are working together in the development and support of clinical trials (studies). A list of SARC trials is provided here with a brief description and patient accrual status. Additionally, the National Institutes of Health provides an online registry and results database of clinical studies conducted around the world.
Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
TYPE OF SARCOMA: Advanced Dedifferentiated LiposarcomaDRUG: AbemaciclibACCRUAL STATUS: Recruiting
A Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
TYPE OF SARCOMA: OsteosarcomaDRUG: Regorafenib, NivolumabACCRUAL STATUS: Recruiting
A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3’-Deoxy-3’-18F Fluorothymidine (18F-FLT) Imaging
TYPE OF SARCOMA: Ewing Sarcoma DRUG: Trabectedin and Irinotecan ACCRUAL STATUS: Recruiting
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
TYPE OF SARCOMA: Epithelioid Hemangioendothelioma DRUG: Trametinib ACCRUAL STATUS: Not recruiting
A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity
TYPE OF SARCOMA: Soft Tissue Sarcoma of the Extremity DRUG: Pembrolizumab ACCRUAL STATUS: Recruiting
A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
TYPE OF SARCOMA: Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve Sheath Tumors (MPNST) DRUG: Selumetinib in Combination with Sirolimus ACCRUAL STATUS: Not recruiting
A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
TYPE OF SARCOMA: Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas, Rhabdomyosarcoma, Mesenchymal Chondrosarcoma DRUG: Regorafenib ACCRUAL STATUS: Not recruiting
© 2023 Sarcoma Alliance For Research Through Collaboration
Sign up for our monthly SARC newsletter and updates on clinical trials.